Page 35 - Haematologica Vol. 107 - September 2022

REVIEW ARTICLE - ITP: diagnosis and second-line treatment J.B. Bussel and C.A. Garcia References
1. Miltiadous O, Hou M, Bussel JB. Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment. Blood. 2020;135(7):472-490.
2. Mithoowani S, Gregory-Miller K, Goy J, et al. High-dose dexamethasone compared with prednisone for previously untreated primary immune thrombocytopenia: a systematic review and meta-analysis. Lancet Haematol. 2016;3(10):e489-e496.
3. Goel R, Chopra S, Tobian AAR, et al. Platelet transfusion practices in immune thrombocytopenia related hospitalizations. Transfusion. 2019;59(1):169-176.
4. Neunert C, Terrell DR, Arnold DM. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829-3866.
5. Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3(22):3780-3817.
6. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386-2393.
7. VanderMeulen H, Sholzberg M. Iron deficiency and anemia in patients with inherited bleeding disorders. Transfus Apher Sci. 2018;57(6):735-738.
8. Maric D. Effect of the successive application of estradiol and progesterone on the number of blood platelets of the rabbit. C R Seances Soc Biol Fil. 1960;154:1865-1866.
9. Onel K, Bussel JB. Adverse effects of estrogen therapy in a subset of women with ITP. J Thromb Haemost. 2004;2(4):670-671.
10. Ho HE, Cunningham-Rundles C. Non-infectious complications of common variable immunodeficiency: updated clinical spectrum, sequelae, and insights to pathogenesis. Front Immunol. 2020;11:149.
11. Grace RF, Lambert MP. An update on pediatric immune thrombocytopenia (ITP): differentiating primary ITP, IPD, and PID. Blood. 2021 Sep 3. [Epub ahead of print].
12. Khellaf M, Chabrol A, Mahevas M, et al. Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies. Am J Hematol. 2014;89(2):194-198.
13. Aggarwal M, Mahapatra M, Seth T, Tyagi S, Tandon N, Saxena R. Thyroid dysfunction in patients with immune thrombocytopenia: prevalence and it's impact on outcome. Indian J Hematol Blood Transfus. 2022;38(1):173-177.
14. Velayutham K, Selvan SS, Unnikrishnan AG. Prevalence of thyroid dysfunction among young females in a South Indian population. Indian J Endocrinol Metab. 2015;19(6):781-784.
15. Unnikrishnan AG, Kalra S, Sahay RK, Bantwal G, John M, Tewari N. Prevalence of hypothyroidism in adults: an epidemiological study in eight cities of India. Indian J Endocrinol Metab. 2013;17(4):647-652.
16. Cordiano I, Betterle C, Spadaccino CA, Soini B, Girolami A, Fabris F. Autoimmune thrombocytopenia (AITP) and thyroid autoimmune disease (TAD): overlapping syndromes? Clin Exp Immunol. 1998;113(3):373-378.
17. McMillan R, Bussel JB, George JN, Lalla D, Nichol JL. Self- reported health-related quality of life in adults with chronic immune thrombocytopenic purpura. Am J Hematol. 2008;83(2):150-154.
18. Mahevas M, Moulis G, Andres E, et al. Clinical characteristics, management and outcome of COVID-19-associated immune thrombocytopenia: a French multicentre series. Br J Haematol. 2020;190(4):e224-e229.
19. DiMaggio D, Anderson A, Bussel JB. Cytomegalovirus can make immune thrombocytopenic purpura refractory. Br J Haematol. 2009;146(1):104-112.
20. Shragai T, Lebel E, Deshet D, et al. Characteristics and outcomes of adults with cytomegalovirus-associated thrombocytopenia: a case series and literature review. Br J Haematol. 2020;191(5):863-867.
21. Stasi R, Sarpatwari A, Segal JB, et al. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review. Blood. 2009;113(6):1231-1240.
22. Zhang H, Chien M, Hou Y, et al. Longitudinal study of 2 patients with cyclic thrombocytopenia, STAT3, and MPL mutations. Blood Adv. 2022 Apr 5. [Epub ahead of print].
23. Pecci A, Balduini CL. Inherited thrombocytopenias: an updated guide for clinicians. Blood Rev. 2021;48:100784.
24. Balduini C, Freson K, Greinacher A, et al. The EHA research roadmap: platelet disorders. Hemasphere. 2021;5(7):e601.
25. Balduini CL, Melazzini F, Pecci A. Inherited thrombocytopenias- recent advances in clinical and molecular aspects. Platelets. 2017;28(1):3-13.
26. Chapin J, Lee CS, Zhang H, Zehnder JL, Bussel JB. Gender and duration of disease differentiate responses to rituximab- dexamethasone therapy in adults with immune thrombocytopenia. Am J Hematol. 2016;91(9):907-911.
27. Lucchini E, Zaja F, Bussel J. Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019? Haematologica. 2019;104(6):1124-1135.
28. Nazi I, Kelton JG, Larche M, et al. The effect of rituximab on vaccine responses in patients with immune thrombocytopenia. Blood. 2013;122(11):1946-1953.
29. Lee EJ, Beltrami-Moreira M, Al-Samkari H, et al. SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITP. Blood. 2022;139(10):1564-1574.
30. Bradbury CA, Pell J, Hill Q, et al. Mycophenolate mofetil for first-line treatment of immune thrombocytopenia. N Engl J Med. 2021;385(10):885-895.
31. Boruchov DM, Gururangan S, Driscoll MC, Bussel JB. Multiagent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP). Blood. 2007;110(10):3526-3531.
32. Reiner A, Gernsheimer T, Slichter SJ. Pulse cyclophosphamide therapy for refractory autoimmune thrombocytopenic purpura. Blood. 1995;85(2):351-358.
33. Bussel JB, Kuter DJ, George JN, et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med. 2006;355(16):1672-1681.
34. Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007;357(22):2237-2247.
35. Bussel JB, Kuter DJ, Aledort LM, et al. A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. Blood. 2014;123(25):3887-3894.
36. Ghanima W, Cooper N, Rodeghiero F, Godeau B, Bussel JB. Thrombopoietin receptor agonists: ten years later. Haematologica. 2019;104(6):1112-1123.
Haematologica | 107 September 2022
2034